ARRY - Array BioPharma Inc.
| Previous Close | 22.71 |
| Open | 22.94 |
| Bid | 23.17 x 800 |
| Ask | 23.50 x 800 |
| Day's Range | 22.84 - 23.76 |
| 52 Week Range | 12.56 - 23.76 |
| Volume | 3,726,540 |
| Avg. Volume | 3,300,656 |
| Market Cap | 5.071B |
| Beta (3Y Monthly) | 1.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.53 |
| Earnings Date | May 7, 2019 - May 13, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.82 |
- PR Newswire•2 days ago
Array BioPharma to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference
BOULDER, Colo. , Feb. 21, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the SVB Leerink Partners 8 th Annual Global ...
- Zacks•9 days ago
Zoetis (ZTS) Beats on Q4 Earnings & Sales, Shares Up
Zoetis (ZTS) exceeds both earnings and sales expectations in the fourth quarter of 2018.
- Markit•15 days ago
See what the IHS Markit Score report has to say about Array Biopharma Inc.
Array Biopharma Inc NASDAQ NMS:ARRYView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for ARRY with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 10. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ARRY totaled $3.24 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Thomson Reuters StreetEvents•16 days ago
Edited Transcript of ARRY earnings conference call or presentation 5-Feb-19 2:00pm GMT
Q2 2019 Array Biopharma Inc Earnings Call
- Zacks•17 days ago
Will Array BioPharma Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Array BioPharma.
- Zacks•17 days ago
Array BioPharma (ARRY) Soars: Stock Adds 11% in Session
Array BioPharma (ARRY) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
- Benzinga•17 days ago
The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 5) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Array ...
- TheStreet.com•18 days ago
Array BioPharma Surges as Loss Is Narrower Than Expected
rose 11% on strong revenue growth and after its loss for its fiscal second quarter was narrower than expectations. The company -- with several drugs in its development pipeline -- posted a loss for the period ended Dec. 31, of 5 cents a share. The loss was narrower than the Zacks Consensus Estimate of 16 cents and its loss the same quarter the previous year of 17 cents.
- Motley Fool•18 days ago
Here's What Sent Array BioPharma Soaring 11.3% Today
Investors rushed to buy shares after the company detailed its latest progress.
Motley Fool•18 days agoArray Biopharma Inc (ARRY) Q2 2019 Earnings Conference Call Transcript
ARRY earnings call for the period ending December 31, 2018.
- American City Business Journals•18 days ago
Boulder biotech firm's skin cancer drugs drive 'strong' second quarter
A Boulder-based biotech company that has recently transitioned to a fully-integrated firm with drugs on the market and a pipeline of new cancer-fighting products on the way reported a strong second quarter mostly due to sales of its new drug combo that combats melanoma. "This was another strong quarter for us," said CEO Ron Squarer. The revenue growth is attributed to the sale of its skin cancer-fighting drug combination Braftovi and Mektovi.
- Zacks•18 days ago
Here's Why Array BioPharma (ARRY) is a Great Momentum Stock to Buy
Does Array BioPharma (ARRY) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks•18 days ago
Array BioPharma (ARRY) Upgraded to Buy: Here's What You Should Know
Array BioPharma (ARRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks•18 days ago
Array BioPharma (ARRY) Reports Q2 Loss, Tops Revenue Estimates
Array BioPharma (ARRY) delivered earnings and revenue surprises of 68.75% and 68.41%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•18 days ago
Array BioPharma: Fiscal 2Q Earnings Snapshot
The Boulder, Colorado-based company said it had a loss of 5 cents per share. The results beat Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was ...
- PR Newswire•18 days ago
Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2019
- Strong quarter for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. with $22.7 million in net product sales, which represents quarter over quarter growth of 62% - - Combination of BRAFTOVI, MEKTOVI ...
- Motley Fool•20 days ago
Here's Why Array BioPharma Jumped 31% in January
Investors had more than one reason to feel good about Array BioPharma last month.
- Simply Wall St.•24 days ago
Does Array BioPharma Inc.’s (NASDAQ:ARRY) CEO Pay Compare Well With Peers?
Ron Squarer became the CEO of Array BioPharma Inc. (NASDAQ:ARRY) in 2012. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'll Read More...
- PR Newswire•25 days ago
Array BioPharma to Report Financial Results for the Second Quarter of Fiscal 2019 on February 5, 2019
BOULDER, Colo. , Jan. 29, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the second quarter of fiscal 2019 and hold a conference call to discuss those results ...
- Zacks•25 days ago
Array BioPharma (ARRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Array BioPharma (ARRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•25 days ago
Has Array BioPharma (ARRY) Outpaced Other Medical Stocks This Year?
Is (ARRY) Outperforming Other Medical Stocks This Year?
- Zacks•last month
Moving Average Crossover Alert: Array BioPharma
Array BioPharma Inc. (ARRY) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
- Zacks•last month
What Makes Array BioPharma (ARRY) a Strong Momentum Stock: Buy Now?
Does Array BioPharma (ARRY) have what it takes to be a top stock pick for momentum investors? Let's find out.
- MarketWatch•last month
Here’s your guide to the upcoming biotechnology takeover wave
Biotechnology companies have been hit so hard, Big Pharma is now picking them off one by one in takeovers. This makes biotech companies look very attractive. In the weakness, for example, Celgene (CELG) hit its lowest price-to-earnings ratio in history, or around six.
